Dow Rises by 300 Points; Waldencast Stock Takes a Dive

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Nov 24 2025

0mins

ENLV0%

INHD+8.04%

TWNP-68.92%

Should l Buy ENLV?

Source: Benzinga

U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.
Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.
Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.
Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ENLV?" and start using high-conviction signals backed by rigorous historical data.

ENLV

$1.16+Infinity%1D

Analyst Views on ENLV

About ENLV

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Enlivex Therapeutics' RAIN Token Listed on KuCoin, Expected to Enhance Liquidity

Jan 14 2026Benzinga

RAIN Token Listing: Enlivex Therapeutics reported that its RAIN token was listed on KuCoin on January 6, with KuCoin serving over 40 million users primarily in Southeast Asia, which is expected to enhance global market access and liquidity for RAIN.
Digital Asset Strategy: Enlivex has launched a digital asset treasury strategy focused on acquiring RAIN tokens, aiming to implement the first RAIN prediction markets token treasury strategy while continuing to develop its core business operations.
Market Potential Analysis: HC Wainwright noted that RAIN's unique 'buy and burn' mechanism could significantly reduce token supply, projecting that if prediction markets reach $1 trillion in annual volume, RAIN could burn approximately $1.25 billion worth of tokens by capturing a 5% market share.
Analyst Rating Upgrade: Analyst Raghuram Selvaraju reiterated a 'Buy' rating for ENLV and raised the price target from $7 to $13, reflecting dilution from the recent PIPE transaction and incorporating the value of RAIN tokens on Enlivex's balance sheet.

Enlivex Adopts First RAIN Prediction Market Token Strategy, Secures $212 Million Funding

Nov 26 2025Globenewswire

Successful Funding: Enlivex has successfully closed a $212 million private investment, which will be utilized to implement the RAIN prediction market token treasury strategy, thereby enhancing the company's competitiveness in the digital asset space.
Innovative Strategy: By adopting RAIN tokens as its primary treasury reserve asset, Enlivex not only provides investors with exposure to emerging digital capital but also demonstrates its forward-thinking approach in blockchain technology applications.
Market Potential: The clinical development of Allocetra™ targets knee osteoarthritis, affecting over 300 million people globally, with projections indicating that 78 million Americans will be impacted by 2040, highlighting the significant market demand and potential returns for this therapeutic solution.
Leadership Enhancement: Former Italian Prime Minister Matteo Renzi joining the Enlivex Board brings extensive leadership experience and a deep understanding of innovation, further elevating the company's strategic vision and market influence.

Three Penny Stocks to Keep an Eye On as of November 25, 2025

Nov 25 2025TipRanks

Penny Stocks to Watch: Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are highlighted as top penny stocks to monitor on November 25, 2025, based on their high Dollar Volume and market activity.
Antelope Enterprise Holdings: The company experienced a significant stock price surge of 109% with a Dollar Volume of $257.38 million, despite no specific news to explain the increase.
Enlivex Therapeutics: This clinical-stage biotechnology firm saw a 13.7% stock price increase and a Dollar Volume of $212.74 million following the announcement of a $212 million private placement for a digital asset treasury strategy involving RAIN tokens.
Inno Holdings: The trade-focused building technology company had a Dollar Volume of $163.23 million but faced a nearly 34% decline in stock price after an initial surge of over 230% due to a strategic partnership announcement with Megabyte Solutions.